VANCOUVER, Canada and LADENBURG, Germany I January 08, 2018 I Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and Heidelberg Pharma announced today advances in their collaborative activities. The companies have agreed to test the combination of APC’s proprietary site-selective protein modification technology and Heidelberg Pharma’s proprietary ATAC technology in order to generate superior cancer therapeutics.
Since the inception of the partnership, activities have been centered on antibody-amanitin conjugates that are produced using controlled conjugation methods and possess high target-specific cytotoxic potency. The companies have successfully demonstrated the generation of ATACs using APC’s proprietary protein modification technology.
“In a first step, we have succeeded in producing ADCs that are sufficiently cytotoxic to target-expressing cancer cell lines to proceed to the next level of in vivo testing. Results obtained from this collaboration will help us to increase the efficacy of our ATACs”, commented Professor Andreas Pahl, CSO of Heidelberg Pharma.
“We are delighted that the partnership with Heidelberg Pharma has generated positive results and look forward to continuing our work together, to the benefit of both companies”, commented Randal Chase, CEO of Advanced Proteome Therapeutics.
APC’s technology aims at the coupling of a cytotoxic payload site-selectively to an antibody of interest without the necessity of genetically engineering such antibody. This may lead to more homogeneous products with certain additional advantages such as an increase in stability in the circulation, fewer side effects and facilitating further pre-clinical and clinical drug development.
About Advanced Proteome Therapeutics
Advanced Proteome Therapeutics Corporation (APC) (TSX VENTURE: APC) (FRANKFURT: 0E8) is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells. Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential. www.advancedproteome.com
About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and REDECTANE®, while RENCAREX® is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.
SOURCE: Heidelberg Pharma
Post Views: 30
VANCOUVER, Canada and LADENBURG, Germany I January 08, 2018 I Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and Heidelberg Pharma announced today advances in their collaborative activities. The companies have agreed to test the combination of APC’s proprietary site-selective protein modification technology and Heidelberg Pharma’s proprietary ATAC technology in order to generate superior cancer therapeutics.
Since the inception of the partnership, activities have been centered on antibody-amanitin conjugates that are produced using controlled conjugation methods and possess high target-specific cytotoxic potency. The companies have successfully demonstrated the generation of ATACs using APC’s proprietary protein modification technology.
“In a first step, we have succeeded in producing ADCs that are sufficiently cytotoxic to target-expressing cancer cell lines to proceed to the next level of in vivo testing. Results obtained from this collaboration will help us to increase the efficacy of our ATACs”, commented Professor Andreas Pahl, CSO of Heidelberg Pharma.
“We are delighted that the partnership with Heidelberg Pharma has generated positive results and look forward to continuing our work together, to the benefit of both companies”, commented Randal Chase, CEO of Advanced Proteome Therapeutics.
APC’s technology aims at the coupling of a cytotoxic payload site-selectively to an antibody of interest without the necessity of genetically engineering such antibody. This may lead to more homogeneous products with certain additional advantages such as an increase in stability in the circulation, fewer side effects and facilitating further pre-clinical and clinical drug development.
About Advanced Proteome Therapeutics
Advanced Proteome Therapeutics Corporation (APC) (TSX VENTURE: APC) (FRANKFURT: 0E8) is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells. Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential. www.advancedproteome.com
About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and REDECTANE®, while RENCAREX® is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.
SOURCE: Heidelberg Pharma
Post Views: 30
